KNSA
Kiniksa Pharmaceuticals LtdNASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$3.75B
P/E Ratio
65.25
EPS
$0.75
Beta
0.06
52W High
$50.03
52W Low
$18.29
50-Day MA
$45.49
200-Day MA
$38.61
Dividend Yield
—
Profit Margin
8.71%
Forward P/E
59.52
PEG Ratio
—
About Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals Ltd. (KNSA) is an innovative biopharmaceutical company focused on developing transformative therapies to meet significant unmet medical needs. Its leading candidate, KPL-404, is a targeted monoclonal antibody designed to inhibit B and T lymphocyte activity, offering new therapeutic avenues for various autoimmune disorders. With a strong pipeline and a commitment to scientific excellence, Kiniksa is well-positioned for growth, supported by strategic collaborations and ongoing clinical trials. The company's efforts could potentially redefine treatment paradigms within the biopharmaceutical sector, making it an attractive investment opportunity for institutional investors.
Fundamentals
| Revenue (TTM) | $677.56M |
| Gross Profit (TTM) | $370.35M |
| EBITDA | $78.78M |
| Operating Margin | 9.78% |
| Return on Equity | 11.70% |
| Return on Assets | 7.18% |
| Revenue/Share (TTM) | $9.13 |
| Book Value | $7.44 |
| Price-to-Book | 6.58 |
| Price-to-Sales (TTM) | 5.53 |
| EV/Revenue | 4.915 |
| EV/EBITDA | 42.28 |
| Quarterly Earnings Growth (YoY) | 550.00% |
| Quarterly Revenue Growth (YoY) | 65.00% |
| Shares Outstanding | $45.90M |
| Float | $39.90M |
| % Insiders | 3.48% |
| % Institutions | 103.91% |
Analyst Ratings
Consensus ($57.38 target)
1
Strong Buy7
BuyData last updated: 4/8/2026